X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/syndax-presents-positive-pediatric-data-from-pivotal-augment-101-trial-of-revumenib-in-relapsedrefractory-kmt2ar-acute-leukemia-at-aspho-plenary-session-302109899.html
https://www.prnewswire.com/news-releases/syndax-announces-fda-priority-review-of-nda-for-revumenib-for-the-treatment-of-relapsedrefractory-kmt2ar-acute-leukemia-302100145.html
https://www.prnewswire.com/news-releases/syndax-presents-positive-data-from-pivotal-augment-101-trial-of-revumenib-in-relapsedrefractory-kmt2ar-acute-leukemia-at-late-breaking-oral-presentation-during-65th-ash-annual-meeting-302012255.html
https://ir.syndax.com/news-releases/news-release-details/syndax-announces-positive-data-revumenib-patients-acute
https://www.prnewswire.com/news-releases/syndax-to-host-investor-event-to-discuss-axatilimab-and-revumenib-data-updates-at-65th-ash-annual-meeting-302003796.html
https://www.prnewswire.com/news-releases/syndax-announces-data-from-pivotal-augment-101-trial-of-revumenib-in-relapsedrefractory-kmt2ar-acute-leukemia-selected-as-late-breaking-presentation-at-the-65th-ash-annual-meeting-301994242.html
https://www.prnewswire.com/news-releases/syndax-announces-updated-data-supporting-impressive-clinical-profile-of-revumenib-in-genetically-defined-acute-leukemias-to-be-presented-at-the-65th-ash-annual-meeting-301975607.html
https://www.prnewswire.com/news-releases/syndax-to-initiate-nda-submission-of-revumenib-in-relapsedrefractory-kmt2ar-acute-leukemia-under-fdas-real-time-oncology-review-program-301965167.html
https://ir.syndax.com/news-releases/news-release-details/syndax-announces-pivotal-augment-101-trial-revumenib
https://www.prnewswire.com/news-releases/syndax-to-announce-topline-results-from-pivotal-augment-101-trial-of-revumenib-in-relapsedrefractory-kmt2ar-acute-leukemia-and-host-an-investor-call-on-october-2-2023-301943343.html
https://www.europeanpharmaceuticalreview.com/news/180602/novel-small-molecule-drug-facilitates-leukaemia-remission/
Market Place
Share 
